

CONTENTS

<i>Contributors</i>	<i>ix</i>
<i>Preface</i>	<i>xiii</i>
<i>Volumes in Series</i>	<i>xv</i>

Section I. Antibodies **1**

1. Simplified Synthetic Antibody Libraries **3**

Saravanan Rajan and Sachdev S. Sidhu

1. Introduction	4
2. Materials	6
3. Methods	8
References	22

2. Generation of Dual-Variable-Domain Immunoglobulin Molecules for Dual-Specific Targeting **25**

Jijie Gu and Tariq Ghayur

1. Introduction	26
2. Design of DVD-Ig TM Molecules	28
3. Cloning and Expression of DVD-Ig TM Molecules	31
4. Molecular Characterization of DVD-Ig TM Proteins	36
5. Functional Characterization of DVD-Ig TM Proteins	38
6. Concluding Remarks	40
Acknowledgments	40
References	40

3. Discovery of Internalizing Antibodies to Tumor Antigens from Phage Libraries **43**

Yu Zhou and James D. Marks

1. Introduction	44
2. Selection of Tumor Cell-Specific Internalizing scFv from Phage Antibody Libraries	48
3. Profiling the Specificity of Phage Antibodies on Tumor Cells Using Flow Cytometry	52
4. Identification of the Cognate Antigen Recognized by Tumor-Specific scFv by Using Mass Spectrometry	53

5. Selection of Antigen-Specific Phage Antibodies by Sequential Selection on Tumor Cells Followed by Selection on Yeast Cells Displaying Specific Tumor Antigens	58
References	63
4. Optimizing Properties of Antireceptor Antibodies Using Kinetic Computational Models and Experiments	67
Brian D. Harms, Jeffrey D. Kearns, Stephen V. Su, Neeraj Kohli, Ulrik B. Nielsen, and Birgit Schoeberl	
1. Introduction: Valence, Affinity, and Avidity in Antibodies	68
2. Quantifying Antibody Cross-linking Strength Using "VFC" Models of Antibody Binding to Cell-Surface Receptors	69
3. Workflow for Quantifying Antibody Cross-linking Strength	73
4. Model Applications and Insights	78
Acknowledgments	86
References	86
Section II. Protein Conjugates	89
5. Cell-Specific siRNA Delivery by Peptides and Antibodies	91
Sang-Kyung Lee, Alyssa Siefert, Jagadish Beloor, Tarek M. Fahmy, and Priti Kumar	
1. Introduction	92
2. Cationic Cell Permeable Peptides	92
3. Solid Biodegradable Polymer and Vesicular (Liposomal) Systems	109
Acknowledgments	118
References	118
6. Conjugation of Anticancer Drugs Through Endogenous Monoclonal Antibody Cysteine Residues	123
Robert P. Lyon, David L. Meyer, Jocelyn R. Setter, and Peter D. Senter	
1. Antibody Reduction	124
2. Monitoring Antibody Reduction	127
3. Conjugation with Maleimido Drug-Linker	128
4. Purification Methods	128
5. Small-Scale Conjugations for Early ADC Discovery	129
6. Procedure for Solid-Phase Conjugation	132
7. Determination of Drug Loading	133
8. Determination of Unconjugated Drug Content	136
9. Conclusions	137
References	137

7. Building and Characterizing Antibody-Targeted Lipidic Nanotherapeutics	139
Dmitri B. Kirpotin, Charles O. Noble, Mark E. Hayes, Zhaohua Huang, Tad Kornaga, Yu Zhou, Ulrik B. Nielsen, James D. Marks, and Daryl C. Drummond	
1. Introduction	140
2. Preparation of Immunoliposomes	143
3. Physicochemical Characterization of Immunoliposomes	157
4. <i>In Vitro</i> and <i>In Vivo</i> Characterization of Immunoliposomal Therapeutics	160
References	164
8. Cell-Targeting Fusion Constructs Containing Recombinant Gelonin	167
Mi-Ae Lyu, Yu (Joshua) Cao, Khalid A. Mohamedali, and Michael G. Rosenblum	
1. Introduction	168
2. Engineered Proteins Targeting Her2/neu	169
3. rGel/BLyS Targeting Malignant B-Cells	181
4. VEGF ₁₂₁ /rGel Targeting Tumor Vasculature and Skeletal Metastases	195
References	210
9. Fusions of Elastin-Like Polypeptides to Pharmaceutical Proteins	215
Wafa Hassounah, Sarah R. MacEwan, and Ashutosh Chilkoti	
1. Introduction	216
2. Protein ELP Fusion Design	218
3. Recursive Directional Ligation by Plasmid Reconstruction	221
4. Expression and Purification of Protein ELP Fusions	228
5. Physical Characterization of Protein ELP Fusions	233
6. Conclusions	235
Acknowledgment	236
References	236
Section III. ENZYMES	239
10. Oral Enzyme Therapy for Celiac Sprue	241
Michael T. Bethune and Chaitan Khosla	
1. Introduction	242
2. Lead Identification	245
3. Assay Development	248
4. Gram-Scale Production and Formulation	259
5. Lead Optimization for Next-Generation Proteases	261

6. Summary and Outlook	264
References	266
11. Rational Design and Evaluation of Mammalian Ribonuclease Cytotoxins	273
Jo E. Lomax, Chelcie H. Eller, and Ronald T. Raines	
1. Introduction	274
2. Attributes of Cytotoxic ptRNases	276
3. Assays to Evaluate the Cytotoxicity of ptRNases	280
4. Prospectus	287
Acknowledgments	287
References	287
12. Engineering Reduced-Immunogenicity Enzymes for Amino Acid Depletion Therapy in Cancer	291
Jason R. Cantor, Vasiliki Panayiotou, Giulia Agnello, George Georgiou, and Everett M. Stone	
1. Introduction: Amino Acid Depletion as a Chemotherapeutic Strategy	292
2. Method I. Combinatorial Deimmunization	297
3. Method II. Engineering Therapeutically Relevant Substrate Specificities into a Human Enzyme	302
4. Method III. Improving the Kinetics and Stability of a Human Enzyme	309
5. Concluding Remarks	312
References	314
<i>Author Index</i>	321
<i>Subject Index</i>	339